Printer Friendly

ISIS PHARMACEUTICALS PROMOTES DANIEL KISNER TO CHIEF OPERATING OFFICER

 CARLSBAD, Calif., Feb. 3 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIP), today announced the promotion of Daniel L. Kisner, M.D., to the newly created position of chief operating officer. In this role, Dr. Kisner will have responsibility for business development, regulatory affairs, strategic marketing, product development, legal affairs, administration and human resources. Stanley T. Crooke, M.D., Ph.D., retains the titles of chairman, president and CEO. Dr. Kisner most recently held the position of executive vice president and member of the board of directors, with responsibility for business development, product development and regulatory affairs. Dr. Kisner will remain on the board of directors.
 "Dan Kisner has assumed an increasing leadership role in the management and development of Isis' business," said Dr. Crooke. "He is an effective spokesman for the company, and his executive contributions have been invaluable. I look forward to Dan playing an even greater role in Isis' growth and continued success."
 Prior to joining Isis, Dr. Kisner was division vice president of pharmaceutical development for Abbott Laboratories where he led an organization of 650 scientists, physicians and support personnel. His responsibilities included preclinical and clinical development of all Abbott Laboratories' ethical pharmaceuticals. Dr. Kisner has also held the position of vice president of clinical research and development for international studies for SmithKline Beecham Corporation, and has held a tenured position in the Division of Oncology at the University of Texas, San Antonio School of Medicine.
 Dr. Kisner received his M.D. from Georgetown University in 1972. He is certified by the American Board of Internal Medicine with a subspecialty in medical oncology. He is the author of more than 50 scientific papers and 40 abstracts in clinical journals and textbooks.
 Isis Pharmaceuticals, based in Northern San Diego County, is engaged in the discovery, development and marketing of novel therapeutic products based in proprietary oligonucleotides. Isis has a broad oligonucleotide research program and its first oligonucleotide based drug, ISIS 2105, is in Phase II clinical trials.
 -0- 2/3/93
 /CONTACT: Stanley T. Crooke, M.D., Ph.D., chairman, president and CEO, or Patricia Lowenstam of Isis, 619-931-9200; or Anthony J. Russo, Ph.D., of Noonan/Russo Communications, 212-979-9180, for Isis/
 (ISIP)


CO: Isis Pharmaceuticals, Inc. ST: California IN: MTC SU: PER

WB-GK -- NY042 -- 2362 02/03/93 11:50 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 3, 1993
Words:383
Previous Article:FRUIT OF THE LOOM CONCLUDES RECORD-BREAKING YEAR: NET EARNINGS UP 61 PERCENT FOR THE YEAR
Next Article:MAPCO DECLARES DIVIDEND
Topics:


Related Articles
ISIS PHARMACEUTICALS APPOINTS JACQUELINE G. SIEGEL CHIEF FINANCIAL OFFICER
ISIS PHARMACEUTICALS APPOINTS JOSEPH WENDER TO BOARD
ISIS PHARMACEUTICALS NAMES DANIEL L. KISNER, M.D., PRESIDENT
RICHARD LAI FATT JOINS ISIS PHARMACEUTICALS AS VP, STRATEGIC MARKETING AND PLANNING
DANIEL KISNER, M.D. JOINS ANESTA'S BOARD OF DIRECTORS
Isis Pharmaceuticals Appoints Burkhard Blank, M.D. to Board of Directors

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters